1. Home
  2. BW vs CHRS Comparison

BW vs CHRS Comparison

Compare BW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$4.93

Market Cap

614.4M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.39

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
CHRS
Founded
1867
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
614.4M
186.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BW
CHRS
Price
$4.93
$1.39
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.50
$4.02
AVG Volume (30 Days)
3.2M
959.3K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.34
Revenue
$721,285,000.00
$277,728,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.85
$67.29
P/E Ratio
N/A
$2.58
Revenue Growth
80.30
152.07
52 Week Low
$0.22
$0.71
52 Week High
$7.77
$1.89

Technical Indicators

Market Signals
Indicator
BW
CHRS
Relative Strength Index (RSI) 40.68 53.23
Support Level $4.57 $1.31
Resistance Level $6.49 $1.41
Average True Range (ATR) 0.60 0.09
MACD -0.25 0.02
Stochastic Oscillator 13.62 77.34

Price Performance

Historical Comparison
BW
CHRS

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: